journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Anticancer Therapy

journal
https://www.readbyqxmd.com/read/28537815/anticancer-treatments-and-female-fertility-clinical-concerns-and-role-of-oncologists-in-oncofertility-practice
#1
Mahmoud Salama, Teresa K Woodruff
Anticancer treatments such as aggressive chemotherapy and radiotherapy have deleterious gonadotoxic side effects and are considered the most common causes of pathological and iatrogenic fertility loss in women. Areas Covered: In order to preserve fertility of young women and girls with cancer, several established, experimental, and debatable options can be offered in the emerging field of oncofertility. This article reviews the effects of anticancer treatments on female fertility and discusses the current challenges and future directions of fertility preservation options that can be offered to the female patients with cancer...
May 24, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28532278/tackling-non-metastatic-castration-resistant-prostate-cancer-special-considerations-in-treatment
#2
Archana Anantharaman, Eric J Small
Prostate cancer (PCa) is currently the second most common cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is the incurable form of PCa, carrying the poorest prognosis, and can develop from non-metastatic CRPC (M0 CRPC). CRPC is defined as progression of the disease with castrate level testosterone levels, achieved with primary androgen deprivation therapy (ADT). M0 CRPC is a highly heterogeneous disease process lacking clear standard of care therapies. Areas covered: In this review, a broad literature search was undertaken to explore data available for therapeutic options and guidelines in the management of M0 CRPC...
May 23, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28511612/ngs-analysis-on-tumor-tissue-and-cfdna-for-genotype-directed-therapy-in-metastatic-nsclc-patients-between-hope-and-hype
#3
Alexander T Falk, Simon Heeke, Véronique Hofman, Virginie Lespinet, Camille Ribeyre, Olivier Bordone, Michel Poudenx, Josiane Otto, Georges Garnier, Olivier Castelnau, Joël Guigay, Sylvie Leroy, Charles-Hugo Marquette, Paul Hofman, Marius Ilié
The advent of genomic based precision medicine led to the implementation of biomarker testing in metastatic non-small cell lung cancer (NSCLC) patients. Next generation sequencing (NGS) has been recently implemented to routine diagnostic requirements in lung oncology. Areas covered: Two cases of patients with metastatic NSCLC for whom NGS analysis performed on both tumor and liquid biopsy has not improved the clinical course of their disease are reported. These cases illustrate the difficulty of the so-called "personalized or precision" medicine in clinical routine practice for metastatic NSCLC...
May 17, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28508703/increased-risk-of-arterial-thromboembolic-events-with-combination-lenalidomide-dexamethasone-therapy-for-multiple-myeloma
#4
Satish Maharaj, Simone Chang, Karan Seegobin, Ivan Serrano-Santiago, Lara Zuberi
Cancer associated thrombosis is a leading cause of morbidity and mortality. Research and guidelines have focused on venous thromboembolic events (VTE). Within the past decade, combination lenalidomide and dexamethasone has become a standard of therapy for multiple myeloma and is now widely used. In these patients, the risk of arterial thromboembolic events (ATE) has not been addressed to the same extent as VTE. Areas discussed: Presented is a targeted review of published data on ATE in MM patients on combination lenalidomide/dexamethasone therapy...
May 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28506194/the-use-of-systemic-therapies-to-prevent-progression-of-inflammatory-breast-cancer-which-targeted-therapies-to-add-on-cytotoxic-combinations
#5
Anthony Gonçalves, Audrey Monneur, Patrice Viens, François Bertucci
Inflammatory breast cancer is a rare but frequently fatal disease, essentially because of its high ability to develop distant metastases. Even though the prognosis of IBC was significantly improved by multimodal management, including the systematic use of cytotoxic-based induction, the prognosis remains largely dismal. Areas covered: This review presents the main achievements in the systemic treatment of IBC during the past 30 years. It focuses more specifically on recent results obtained with targeted therapies, including anti-HER2 and anti-angiogenic agents...
May 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28504011/the-future-of-oncology-therapeutics
#6
André Mansinho, Valentina Boni, María de Miguel, Emiliano Calvo
No abstract text is available yet for this article.
May 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28480774/endoscopic-management-of-upper-tract-urothelial-carcinoma
#7
Jay D Raman, Rosa Park
Radical nephroureterectomy with an ipsilateral bladder cuff is the referent standard for management of muscle-invasive, high-grade, or bulky upper-tract urothelial carcinoma (UTUC). Nonetheless, certain patients with UTUC have imperative or elective indications for kidney preservation thereby lending to more conservative strategies for management of this disease. Areas covered: A review of the PubMED and Medline databases was performed to identify original scientific and review articles discussing retrograde ureteroscopic or percutaneous antegrade resection of UTUC tumors published between 1995 and 2016...
May 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28503964/recent-advances-in-intensity-modulated-radiotherapy-and-proton-therapy-for-esophageal-cancer
#8
Mian Xi, Steven H Lin
Radiotherapy is an important component of the standard of care for esophageal cancer. In the past decades, significant improvements in the planning and delivery of radiation techniques have led to better dose conformity to the target volume and improved normal tissue sparing. Areas covered: This review focuses on the advances in radiotherapy techniques and summarizes the availably dosimetric and clinical outcomes of intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, proton therapy, and four-dimensional radiotherapy for esophageal cancer, and discusses the challenges and future development of proton therapy...
May 13, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28447483/the-role-of-adhesions-between-homologous-cancer-cells-in-tumor-progression-and-targeted-therapy
#9
Jie Xia, Yuhao Cheng, Hang Zhang, Rutian Li, Yiqiao Hu, Baorui Liu
Adhesions between homologous cancer cells play an important role in promoting tumor progression and designing tumor-targeting methods. Known as 'homologous adhesions' of cancerous cells, these are usually more specific than adhesions to normal cells and heterogenic cells, and they have been widely discovered both in vivo and in vitro. The aberrant expression of cell adhesion-related molecules (CARMs) on each species of cancer cells is mainly responsible for inducing more specific homologous adhesions. Based on the improvement of biomimetic technologies, such adhesion has been investigated and applied deeply in drug delivery systems recently...
May 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28438066/angiogenesis-inhibitors-in-tackling-recurrent-glioblastoma
#10
Thomas Hundsberger, David A Reardon, Patrick Y Wen
Despite aggressive multimodality treatment of glioblastoma, outcome remains poor and patients mostly die of local recurrences. Besides reoperation and occasionally reirradiation, systemic treatment of recurrent glioblastoma consists of alkylating chemotherapy (lomustine, temozolomide), bevacizumab and combinations thereof. Unfortunately, antiangiogenic agents failed to improve survival either as a monotherapy or in combination treatments. This review provides current insights into tumor-derived escape mechanisms and other areas of treatment failure of antiangiogenic agents in glioblastoma...
May 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28425820/metastatic-soft-tissue-sarcoma-current-treatment-landscape-and-future-perspectives
#11
E Skafida, S Kokkali, M Nikolaou, A Digklia
The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinical stage development demonstrating to be effective in controlled studies. While these novel treatments can be beneficial to a subset of patients, even producing long lasting remissions, a significant fraction of the STS population derives limited benefit...
April 28, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28399672/targeting-adenosine-in-cancer-immunotherapy-a-review-of-recent-progress
#12
Theresa L Whiteside
The adenosine pathway plays a key role in modulating immune responses in health and in disease. In health, anti-inflammatory effects of adenosine balance pro-inflammatory ATP, limiting tissue destruction by activated immune cells. In disease, this balance is disturbed. Areas covered: This review focuses on cancer and explains how in the microenvironment, the ATP-adenosine balance shifts towards an excess of extracellular adenosine Expert commentary: The CD73-adenosine axis plays a key role in the inhibition of anti-tumor functions of immune effector cells...
April 27, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28406334/the-need-for-active-surveillance-for-low-risk-prostate-cancer
#13
Frank-Jan H Drost, Monique J Roobol
No abstract text is available yet for this article.
April 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28403675/advances-in-the-use-of-surgery-and-multimodality-treatment-for-n2-non-small-cell-lung-cancer
#14
Paul E Van Schil, Krishan Yogeswaran, Jeroen M Hendriks, Patrick Lauwers, Corinne Faivre-Finn
Stage IIIA-N2 non-small cell lung cancer (NSCLC) represents a heterogeneous group of bronchogenic carcinomas with locoregional involvement. Different categories of N2 disease exist, ranging from unexpectedly encountered N2 involvement after detailed preoperative staging or 'surprise' N2, to potentially resectable disease treated within a combined modality setting, and finally, bulky N2 involvement treated by chemoradiation. Areas covered: Large randomised controlled trials and meta-analyses on stage IIIA-N2 NSCLC have been published but their implications for treatment remain a matter of debate...
April 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28142287/overview-and-recent-advances-in-the-treatment-of-neuroblastoma
#15
Sarah B Whittle, Valeria Smith, Erin Doherty, Sibo Zhao, Scott McCarty, Peter E Zage
Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma...
March 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28271747/short-term-outcomes-of-neoadjuvant-hormonal-therapy-versus-neoadjuvant-chemotherapy-in-breast-cancer-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#16
Lei Huang, A-Man Xu
Estrogen receptor positive (ER(+)) breast cancer (BC) is highly hormonal therapy-responsive. The choice between neoadjuvant hormonal therapy (NHT) and neoadjuvant chemotherapy (NCT) remains controversial. The aim of this meta-analysis was to evaluate benefits and safety of NHT compared with NCT for operable BC patients. Areas covered: Electronic databases were searched to identify randomized clinical trials (RCTs) comparing NHT and NCT for treatment of invasive and immunohistochemically ER(+) BC. Major outcomes were clinical response rate, pathologic complete response (pCR), operation methods, recurrence, and adverse events...
March 8, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28271737/could-nampt-inhibition-become-a-potential-treatment-option-in-hepatocellular-carcinoma
#17
Antje Garten, Susanne Schuster, Melanie Penke
No abstract text is available yet for this article.
March 8, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28277100/statistical-approaches-for-evaluating-body-composition-markers-in-clinical-cancer-research
#18
Mohamed Amine Bayar, Sami Antoun, Emilie Lanoy
The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review statistical approaches used to evaluate these markers and suggest practical statistical recommendations. Area covered: We identified statistical methods used recently to take into account properties of morphomics measurements...
March 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28277101/radiosurgery-stereotactic-radiotherapy-in-combination-with-immunotherapy-and-targeted-agents-for-melanoma-brain-metastases
#19
Elisabetta Trino, Cristina Mantovani, Serena Badellino, Umberto Ricardi, Andrea Riccardo Filippi
The clinical landscape of advanced melanoma drastically changed after the introduction of both targeted therapies and immunotherapy. This rapid development in systemic therapies led to a change in the management of patients with brain metastases, with the subsequent need to re-assess the role of local therapies, in particular stereotactic radiosurgery (SRS). Areas covered: In this non-systematic review, we report on the current knowledge on the use of SRS in combination with immunotherapy and BRAF/MEK inhibitors for patients with melanoma brain metastases, as well as ongoing trials in this field...
March 1, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28480764/novel-agents-in-mantle-cell-lymphoma
#20
David Tucker, Simon Rule
Mantle cell lymphoma (MCL) usually takes an aggressive clinical course and carries a poor prognosis. Recently, progress has been made in the treatment of MCL including the development of a number of novel agents which target intracellular pathways and the extracellular microenvironment. These agents have transformed the landscape of available therapeutic options. Areas covered: The current literature on the novel agents which currently hold a licence for the treatment of MCL in the context of front-line therapy and in the relapsed/refractory setting is summarized...
June 2017: Expert Review of Anticancer Therapy
journal
journal
39793
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"